View on Pubmed.gov 25013808 | View on doi.org 10.1155/2014/87...
PET radiopharmaceuticals for imaging integrin expression: tracers in clinical studies and recent developments.
- Department of Nuclear Medicine, Innsbruck Medical University, Anichstraße 35, 6020 Innsbruck, Austria.
- Molecular Imaging and Radiochemistry, Department of Nuclear Medicine, Friedrich-Alexander University, Schwabachanlage 6, 91054 Erlangen, Germany.
Abstract
Noninvasive determination of integrin expression has become an interesting approach in nuclear medicine. Since the discovery of the first 18F-labeled cyclic RGD peptide as radiotracer for imaging integrin αvβ3 expression in vivo, there have been carried out enormous efforts to develop RGD peptides for PET imaging. Moreover, in recent years, additional integrins, including α5β1 and αvβ6 came into the focus of pharmaceutical radiochemistry. This review will discuss the tracers already evaluated in clinical trials and summarize the preliminary outcome. It will also give an overview on recent developments to further optimize the first-generation compounds such as [18F]Galacto-RGD. This includes recently developed 18F-labeling strategies and also new approaches in 68Ga-complex chemistry. Furthermore, the approaches to develop radiopharmaceuticals targeting integrin α5β1 and αvβ6 will be summarized and discussed.
References
Clin Cancer Res. 2012 Feb 1;18(3):839-49
J Cell Sci. 1995 Jun;108 ( Pt 6):2241-51
J Cell Biol. 1994 Feb;124(3):373-80
Cancer Res. 2009 Jul 15;69(14):5843-50
Cited by 79 citations (total)
Journal Article Research Support, Non-U.S. Gov't
H-CRRETAWAC-OH, a lead structure for the development of radiotracer targeting integrin α5β1?
Electronic publication date July 3, 2015
Roland Haubner [...] Olaf Prante et al.
Imaging of angiogenic processes is of great interest in preclinical research as well as in clinical settings. The most commonly...
Journal Article
Tc-3P-RGD2 molecular imaging targeting integrin in head and neck squamous cancer xenograft.
Electronic publication date August 1, 2015
Bing Yan [...] Feng Wang et al.
Tc-3P-RGD2 and SPECT/CT were valuable tools for selecting patient likely benefit from integrin blocking therapy. To evaluate the feasibility...
Conflict of interest statement
MeSH
- •
- •
Specialties
- •
- •
- •
- •
- •
Substances
- •
- •